Throughout the last three months, 9 analysts have evaluated Janux Therapeutics (NASDAQ:JANX), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
5
3
1
0
0
Last 30D
0
0
1
0
0
1M Ago
1
2
0
0
0
2M Ago
1
0
0
0
0
3M Ago
3
1
0
0
0
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $68.22, a high estimate of $100.00, and a low estimate of $47.00. This current average has increased by 68.44% from the previous average price target of $40.50.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Janux Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
George Farmer
Scotiabank
Announces
Sector Perform
$47.00
-
Swayampakula Ramakanth
HC Wainwright & Co.
Raises
Buy
$63.00
$50.00
Josh Schimmer
Cantor Fitzgerald
Maintains
Overweight
$100.00
-
Robert Driscoll
Wedbush
Raises
Outperform
$74.00
$53.00
Soumit Roy
JonesTrading
Announces
Buy
$70.00
-
Kaveri Pohlman
BTIG
Announces
Buy
$62.00
-
Josh Schimmer
Cantor Fitzgerald
Announces
Overweight
$100.00
-
Geoff Meacham
B of A Securities
Raises
Buy
$48.00
$24.00
Swayampakula Ramakanth
HC Wainwright & Co.
Raises
Buy
$50.00
$35.00
Key Insights:
Action ...Full story available on Benzinga.com
Benzinga
